Related Experiment Video

Updated: May 5, 2026

Microsurgical Clip Obliteration of Middle Cerebral Aneurysm Using Intraoperative Flow Assessment
18:50

Microsurgical Clip Obliteration of Middle Cerebral Aneurysm Using Intraoperative Flow Assessment

Published on: September 25, 2009

13.7K

Management of a left anterior descending artery aneurysm in Behçet's disease: A case report

Ahmed Hussein Subki1, Abdurahman Albeity1, Israa Mohammed Mulla1

  • 1Department of Internal Medicine, King Faisal Specialist Hospital & Research Center, P.O. Box 40047, Jeddah 21499, Saudi Arabia.

Modern Rheumatology Case Reports
|January 17, 2025
PubMed

Insights

Behçet

Area of Science:

  • Cardiology
  • Rheumatology
  • Immunology

Background:

  • Behçet's disease is a systemic vasculitis affecting all vessel sizes.
  • Coronary artery aneurysms are a severe complication of Behçet's disease.
  • Management of vascular complications in Behçet's disease remains challenging.

Purpose of the Study:

  • To report a case of a large coronary artery aneurysm in a patient with Behçet's disease.
  • To evaluate the efficacy of infliximab in managing vascular complications of Behçet's disease.
  • To highlight treatment strategies for coronary artery aneurysms in Behçet's disease.

Main Methods:

  • Case report of a 33-year-old woman with Behçet's disease and recurrent chest pain.
  • Diagnostic imaging revealed a left anterior descending artery aneurysm.
  • Treatment included percutaneous coronary interventions and infliximab therapy.

Main Results:

  • Successful stabilization of the coronary artery aneurysm using percutaneous coronary interventions.
  • Infliximab therapy led to clinical remission of Behçet's disease for over three years.
  • Demonstrated sustained control of vasculitis and its vascular manifestations.

Conclusions:

  • Infliximab shows promise in managing vascular complications of Behçet's disease.
  • Combined interventional and medical therapy can be effective for coronary artery aneurysms in Behçet's disease.
  • Further research is needed on long-term infliximab efficacy and safety in Behçet's disease vascular complications.

Keywords:
Behçet’s diseasecoronary artery aneurysminfliximableft anterior descending arteryvasculitis

More Related Videos

Arterial Pouch Microsurgical Bifurcation Aneurysm Model in the Rabbit06:11

Arterial Pouch Microsurgical Bifurcation Aneurysm Model in the Rabbit

Published on: May 14, 2020

2.3K
Creation of Two Saccular Elastase-Digested Aneurysms with Different Hemodynamics in One Rabbit07:04

Creation of Two Saccular Elastase-Digested Aneurysms with Different Hemodynamics in One Rabbit

Published on: April 15, 2021

2.0K

Related Concept Videos

Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
598
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
Aneurysm I: Introduction01:30

Aneurysm I: Introduction

An aortic aneurysm is a localized outpouching or dilation at a weak point in the artery wall. It may involve different parts of the aorta, such as the abdominal aorta, aortic arch, or thoracic aorta.Etiological factorsSeveral disorders are associated with aortic aneurysms.Congenital causes, such as primary connective tissue disorders like Marfan syndrome, impact the integrity and strength of connective tissues, notably affecting the aorta. Marfan syndrome is a genetic disorder that specifically...
650
Aneurysm III: Interprofessional Care01:26

Aneurysm III: Interprofessional Care

Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
478